Medication compliance for people taking psychiatric drugs is notoriously hit and miss. Because of that, the Food and Drug Administration (FDA) recently approved a form of aripiprazole (Abilify) that digitally tracks medication compliance in patients with schizophrenia, some forms of bipolar, and some cases of depression according to Psychiatric Times.1 A digital sensor in the pill tracks when the medication is ingested by sending a digital tracking signal to an arm patch. Information can be provided to patients and might be shared with families and providers. While this may be the first such drug approved by the FDA, it will not be the last. So, the question for mentally ill patients and their families is this: Is this a wonderful, new medication compliance tool, or is it a potentially dangerous invasion of privacy?